Published in J Virol on June 10, 2009
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology (2011) 1.54
A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. PLoS Pathog (2010) 1.38
Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol (2010) 1.33
Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J Virol (2010) 1.19
Tight junctions in the testis: new perspectives. Philos Trans R Soc Lond B Biol Sci (2010) 1.16
Hepatitis C virus induces CD81 and claudin-1 endocytosis. J Virol (2012) 1.14
Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies. PLoS Pathog (2013) 1.08
Species-specific regions of occludin required by hepatitis C virus for cell entry. J Virol (2010) 1.07
Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J Biol Chem (2011) 1.04
Neutralizing antibody response to hepatitis C virus. Viruses (2011) 1.03
Role for ADP ribosylation factor 1 in the regulation of hepatitis C virus replication. J Virol (2010) 0.97
Transient activation of the PI3K-AKT pathway by hepatitis C virus to enhance viral entry. J Biol Chem (2012) 0.97
Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. Clin Dev Immunol (2013) 0.95
Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. MAbs (2014) 0.94
The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. Virology (2010) 0.94
Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses (2011) 0.93
The second extracellular loop dictates Occludin-mediated HCV entry. Virology (2010) 0.92
Hepatitis C virus life cycle and lipid metabolism. Biology (Basel) (2014) 0.91
Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J Virol (2012) 0.91
New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis (2016) 0.91
Human tumour viruses and the deregulation of cell polarity in cancer. Nat Rev Cancer (2012) 0.90
5-HT2 receptors facilitate JC polyomavirus entry. J Virol (2013) 0.89
The SR-BI partner PDZK1 facilitates hepatitis C virus entry. PLoS Pathog (2010) 0.89
Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape? Viruses (2012) 0.88
Hepatitis C virus experimental model systems and antiviral drug research. Virol Sin (2010) 0.87
Bacterial induction of Snail1 contributes to blood-brain barrier disruption. J Clin Invest (2015) 0.87
Recent advances in hepatitis C virus cell entry. Viruses (2010) 0.87
Targeting HCV entry for development of therapeutics. Viruses (2010) 0.86
Permissiveness of human hepatoma cell lines for HCV infection. Virol J (2012) 0.86
Cell-cell contact-mediated hepatitis C virus (HCV) transfer, productive infection, and replication and their requirement for HCV receptors. J Virol (2013) 0.85
AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets. J Virol (2015) 0.85
CD81 and hepatitis C virus (HCV) infection. Viruses (2014) 0.84
Differential expression of candidate virus receptors in human T lymphocytes prone or resistant to infection with patient-derived hepatitis C virus. PLoS One (2013) 0.83
Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII). Viruses (2012) 0.83
Impact of lentiviral vector-mediated transduction on the tightness of a polarized model of airway epithelium and effect of cationic polymer polyethylenimine. J Biomed Biotechnol (2010) 0.83
Apolipoprotein E, but Not Apolipoprotein B, Is Essential for Efficient Cell-to-Cell Transmission of Hepatitis C Virus. J Virol (2015) 0.82
In vitro systems for the study of hepatitis C virus infection. Int J Hepatol (2012) 0.82
Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay. Antimicrob Agents Chemother (2012) 0.81
Hepatic tight junctions: from viral entry to cancer metastasis. World J Gastroenterol (2010) 0.81
Role of conserved cysteine residues in hepatitis C virus glycoprotein e2 folding and function. J Virol (2012) 0.80
Interaction of human tumor viruses with host cell surface receptors and cell entry. Viruses (2015) 0.78
Degradation of AIMP1/p43 induced by hepatitis C virus E2 leads to upregulation of TGF-β signaling and increase in surface expression of gp96. PLoS One (2014) 0.78
Recent advances in understanding hepatitis C. F1000Res (2016) 0.78
Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry. World J Gastroenterol (2011) 0.78
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro. PLoS One (2015) 0.77
Natural killer cell function and dysfunction in hepatitis C virus infection. Biomed Res Int (2014) 0.77
Active RNA replication of hepatitis C virus downregulates CD81 expression. PLoS One (2013) 0.77
Immunohistological characterization of intercellular junction proteins in rhesus macaque intestine. Exp Toxicol Pathol (2014) 0.76
Attachment and Post-Attachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission. J Virol (2017) 0.75
Permeability properties and occludin expression in a primary cultured model gill epithelium from the stenohaline freshwater goldfish. J Comp Physiol B (2010) 0.75
Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus. World J Hepatol (2015) 0.75
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology (1995) 14.30
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol (1995) 7.57
Virus entry: open sesame. Cell (2006) 6.33
Viral hepatitis C. Lancet (2003) 5.81
Unravelling hepatitis C virus replication from genome to function. Nature (2005) 5.25
Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell (2006) 4.68
Junction adhesion molecule is a receptor for reovirus. Cell (2001) 4.00
Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol (2006) 3.75
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape. Cell (2002) 3.53
Coxsackievirus entry across epithelial tight junctions requires occludin and the small GTPases Rab34 and Rab5. Cell Host Microbe (2007) 3.34
Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol (2006) 3.33
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
Clathrin and adaptors. Biochim Biophys Acta (1998) 2.97
Knockdown of occludin expression leads to diverse phenotypic alterations in epithelial cells. Am J Physiol Cell Physiol (2005) 2.92
Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol (2008) 2.84
Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol (2006) 2.50
The tight junction protein complex undergoes rapid and continuous molecular remodeling at steady state. J Cell Biol (2008) 2.42
Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells. Virology (2005) 2.24
CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol (2008) 2.09
Tight junctions: molecular architecture and function. Int Rev Cytol (2006) 2.01
Rab13 mediates the continuous endocytic recycling of occludin to the cell surface. J Biol Chem (2004) 1.78
Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol (2007) 1.59
Early steps of the hepatitis C virus life cycle. Cell Microbiol (2007) 1.51
Effect of cell polarization on hepatitis C virus entry. J Virol (2007) 1.41
Structural integrity of hepatocyte tight junctions. J Cell Biol (1983) 1.25
Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum. Hepatology (2008) 1.23
Interleukin-1beta and barrier function of retinal pigment epithelial cells (ARPE-19): aberrant expression of junctional complex molecules. Invest Ophthalmol Vis Sci (2003) 1.22
Biogenesis of tight junctions: the C-terminal domain of occludin mediates basolateral targeting. J Cell Sci (1998) 0.94
Tight junction targeting and intracellular trafficking of occludin in polarized epithelial cells. Am J Physiol Cell Physiol (2007) 0.90
Centrifugal enhancement of hepatitis C virus infection of human hepatocytes. J Virol Methods (2008) 0.84
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med (2003) 5.01
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem (2003) 4.58
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A (2003) 3.40
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology (2009) 3.28
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med (2010) 3.09
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology (2005) 2.93
Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol (2005) 2.85
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A (2005) 2.42
Characterization of functional hepatitis C virus envelope glycoproteins. J Virol (2004) 2.40
A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. Nucleic Acids Res (2006) 2.38
Molecular basis of xeroderma pigmentosum group C DNA recognition by engineered meganucleases. Nature (2008) 2.37
Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology (2007) 2.25
Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol (2005) 2.19
Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease. Nucleic Acids Res (2009) 2.14
Engineering of large numbers of highly specific homing endonucleases that induce recombination on novel DNA targets. J Mol Biol (2005) 2.04
High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem (2006) 2.02
Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol (2007) 1.94
Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology (2003) 1.93
Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. J Hepatol (2005) 1.93
Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. FASEB J (2009) 1.90
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology (2008) 1.87
Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol (2003) 1.86
Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology (2010) 1.85
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79
Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology (2005) 1.75
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology (2006) 1.75
High levels of transduction of human dendritic cells with optimized SIV vectors. Mol Ther (2002) 1.73
Cell cycle features of primate embryonic stem cells. Stem Cells (2005) 1.64
Low-GDP peritoneal dialysis fluid ('balance') has less impact in vitro and ex vivo on epithelial-to-mesenchymal transition (EMT) of mesothelial cells than a standard fluid. Nephrol Dial Transplant (2010) 1.64
The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J Virol (2008) 1.63
Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol (2002) 1.62
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol (2007) 1.59
Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol (2010) 1.59
Cell entry of hepatitis C virus. Virology (2006) 1.58
Angiogenesis in chronic inflammatory liver disease. Hepatology (2004) 1.57
The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J Clin Invest (2002) 1.55
Inhibiting expression of specific genes in mammalian cells with 5' end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA. Proc Natl Acad Sci U S A (2003) 1.55
Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol (2005) 1.53
Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A (2004) 1.53
The envelope glycoprotein of human endogenous retrovirus type W uses a divergent family of amino acid transporters/cell surface receptors. J Virol (2002) 1.49
Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol (2002) 1.48
Tetraspanins CD9 and CD81 modulate HIV-1-induced membrane fusion. J Immunol (2006) 1.48
Soluble angiogenic factors in patients with acute pancreatitis. J Clin Gastroenterol (2011) 1.47
Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Cell Host Microbe (2009) 1.46
Cardiotrophin-1 reduces ischemia/reperfusion injury during liver transplant. J Surg Res (2012) 1.45
Amphiregulin: an early trigger of liver regeneration in mice. Gastroenterology (2005) 1.44
Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells. Hepatology (2011) 1.44
Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis (2005) 1.42
Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care (2004) 1.42
Evaluation of liver fibrosis by transient elastography in methotrexate treated patients. Med Clin (Barc) (2011) 1.42
Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. J Biol Chem (2005) 1.41
C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem (2004) 1.41
Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. Hepatology (2010) 1.41
A concerted action of hepatitis C virus p7 and nonstructural protein 2 regulates core localization at the endoplasmic reticulum and virus assembly. PLoS Pathog (2011) 1.41
Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses. J Virol (2004) 1.39
Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology (2005) 1.38
Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology (2012) 1.38
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog (2009) 1.36
TLX homeodomain oncogenes mediate T cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRα gene expression. Cancer Cell (2012) 1.36
Moesin is required for HIV-1-induced CD4-CXCR4 interaction, F-actin redistribution, membrane fusion and viral infection in lymphocytes. J Cell Sci (2008) 1.35
Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damage. J Am Soc Nephrol (2011) 1.33
Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology (2007) 1.32
Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing. J Virol (2006) 1.32
Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood (2002) 1.32
The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) (2009) 1.31
Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell (2006) 1.29
Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol (2007) 1.29
HCV and oxidative stress in the liver. Viruses (2013) 1.28
Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood (2008) 1.25
Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol (2005) 1.23
Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum. Hepatology (2008) 1.23